BioCentury
ARTICLE | Company News

Ardelyx, Sanofi deal

March 3, 2014 8:00 AM UTC

Ardelyx granted Sanofi exclusive, worldwide rights to develop and commercialize Ardelyx's RDX002 program of solute carrier family 34 sodium phosphate member 2 ( SLC34A2; NaPi2b) inhibitors. Ardelyx...